Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 72 articles:
HTML format
Text format



Single Articles


    September 2017
  1. WANG X, Zhu Q, Lin Y, Wu L, et al
    Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    August 2017
  2. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  3. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
    Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Br J Cancer. 2017;117:628-638.
    PubMed     Text format     Abstract available


  4. MINLIKEEVA AN, Freudenheim JL, Cannioto RA, Eng KH, et al
    History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  5. CHEN Y, Wang DD, Wu YP, Su D, et al
    MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  6. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Text format     Abstract available


  7. TABUNG FK, Huang T, Giovannucci EL, Smith-Warner SA, et al
    The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    July 2017
  8. MENON U, McGuire AJ, Raikou M, Ryan A, et al
    The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Br J Cancer. 2017 Jul 25. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  9. ITAMOCHI H, Oishi T, Oumi N, Takeuchi S, et al
    Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  10. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  11. SERENI MI, Baldelli E, Gambara G, Ravaggi A, et al
    Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  12. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available


  13. BANDERA EV, Lee VS, Qin B, Rodriguez-Rodriguez L, et al
    Impact of body mass index on ovarian cancer survival varies by stage.
    Br J Cancer. 2017 Jun 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  14. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Text format     Abstract available


    May 2017
  15. PLAYDON MC, Nagle CM, Ibiebele TI, Ferrucci LM, et al
    Pre-diagnosis diet and survival after a diagnosis of ovarian cancer.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  16. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
    Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  17. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  18. DIXON SC, Nagle CM, Wentzensen N, Trabert B, et al
    Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  19. PHELPS DL, Borley JV, Flower KJ, Dina R, et al
    Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  20. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  21. FALLOWFIELD L, Solis-Trapala I, Menon U, Langridge C, et al
    The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  22. SHATHASIVAM P, Kollara A, Spybey T, Park S, et al
    VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  23. KIM SJ, Rosen B, Fan I, Ivanova A, et al
    Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  24. LINDEMANN K, Gibbs E, Avall-Lundqvist E, dePont Christensen R, et al
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
    Br J Cancer. 2017 Jan 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  25. KAR SP, Adler E, Tyrer J, Hazelett D, et al
    Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  26. HEUDEL PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, et al
    Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2016
  27. KOMMOSS S, Kommoss F, Diebold J, Lax S, et al
    Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.
    Br J Cancer. 2016 Dec 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  28. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  29. LICAJ I, Jacobsen BK, Selmer RM, Maskarinec G, et al
    Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  30. LI X, Chen W, Zeng W, Wan C, et al
    microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  31. LEDERMANN JA, Harter P, Gourley C, Friedlander M, et al
    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  32. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  33. KONECNY GE, Kristeleit RS
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  34. SHAFRIR AL, Babic A, Tamimi RM, Rosner BA, et al
    Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  35. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. DONAT-VARGAS C, Akesson A, Berglund M, Glynn A, et al
    Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  37. QIN B, Moorman PG, Alberg AJ, Barnholtz-Sloan JS, et al
    Dairy, calcium, vitamin D and ovarian cancer risk in African-American women.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  38. KOMMOSS S, Gilks CB, du Bois A, Kommoss F, et al
    Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  39. YANG Z, Wang XL, Bai R, Liu WY, et al
    miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  40. FRUSCIO R, Ceppi L, Corso S, Galli F, et al
    Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  41. VAN DER PUTTEN LJ, Visser NC, van de Vijver K, Santacana M, et al
    L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    Br J Cancer. 2016 Aug 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  42. BRONGER H, Singer J, Windmuller C, Reuning U, et al
    CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  43. SAYASNEH A, Ferrara L, De Cock B, Saso S, et al
    Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study.
    Br J Cancer. 2016 Aug 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  44. VAIDYANATHAN A, Sawers L, Gannon AL, Chakravarty P, et al
    ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
    Br J Cancer. 2016 Jul 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  45. CANNIOTO RA, LaMonte MJ, Kelemen LE, Risch HA, et al
    Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2016 Jun 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  46. WANG C, Winterhoff BJ, Kalli KR, Block MS, et al
    Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  47. BROWN JS, Kaye SB, Yap TA
    PARP inhibitors: the race is on.
    Br J Cancer. 2016;114:713-5.
    PubMed     Text format    


  48. RATNER ES, Zhu YL, Penketh PG, Berenblum J, et al
    Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Br J Cancer. 2016;114:777-86.
    PubMed     Text format     Abstract available


  49. DREW Y, Ledermann J, Hall G, Rea D, et al
    Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Br J Cancer. 2016 Mar 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    February 2016
  50. PERES LC, Camacho F, Abbott SE, Alberg AJ, et al
    Analgesic medication use and risk of epithelial ovarian cancer in African American women.
    Br J Cancer. 2016 Feb 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  51. HIRAMATSU K, Yoshino K, Serada S, Yoshihara K, et al
    Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas.
    Br J Cancer. 2016;114.
    PubMed     Text format     Abstract available


  52. HARRINGTON BS, He Y, Davies CM, Wallace SJ, et al
    Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Br J Cancer. 2016;114:417-26.
    PubMed     Text format     Abstract available


    January 2016
  53. SIVALINGAM VN, Kitson S, McVey R, Roberts C, et al
    Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
    Br J Cancer. 2016 Jan 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  54. TRILLSCH F, Kuerti S, Eulenburg C, Burandt E, et al
    E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer.
    Br J Cancer. 2016 Jan 12. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  55. KOTI M, Siu A, Clement I, Bidarimath M, et al
    A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Br J Cancer. 2015;113:1746.
    PubMed     Text format    


  56. DREW Y
    The development of PARP inhibitors in ovarian cancer: from bench to bedside.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


  57. GEORGE A
    UK BRCA mutation testing in patients with ovarian cancer.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


  58. LEDERMANN JA, El-Khouly F
    PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


  59. CIBULA D, Balmana J
    PARP inhibitors in ovarian cancer.
    Br J Cancer. 2015;113.
    PubMed     Text format    


  60. MURRAY MJ, Bell E, Raby KL, Rijlaarsdam MA, et al
    A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.
    Br J Cancer. 2015 Dec 15. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  61. KUMAR J, Fraser FW, Riley C, Ahmed N, et al
    Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
    Br J Cancer. 2015;113:1642-3.
    PubMed     Text format    


    November 2015
  62. BESEVIC J, Gunter MJ, Fortner RT, Tsilidis KK, et al
    Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study.
    Br J Cancer. 2015 Nov 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  63. IKEDA Y, Oda K, Ishihara H, Wada-Hiraike O, et al
    Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
    Br J Cancer. 2015 Nov 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    October 2015
  64. GERSHENSON DM, Sun CC, Wong KK
    Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
    Br J Cancer. 2015 Oct 20. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    September 2015
  65. MENG X, Joosse SA, Muller V, Trillsch F, et al
    Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.
    Br J Cancer. 2015 Sep 22. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  66. KERKLAAN BM, Lolkema MP, Devriese LA, Voest EE, et al
    Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
    Br J Cancer. 2015;113:706-15.
    PubMed     Text format     Abstract available


  67. HASHIBE M, Galeone C, Buys SS, Gren L, et al
    Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
    Br J Cancer. 2015;113:809-16.
    PubMed     Text format     Abstract available


    July 2015
  68. VAN DER NOLL R, Marchetti S, Steeghs N, Beijnen JH, et al
    Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
    Br J Cancer. 2015 Jul 16. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  69. HSU KF, Shen MR, Huang YF, Cheng YM, et al
    Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.
    Br J Cancer. 2015 Jul 9. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  70. NAGLE CM, Dixon SC, Jensen A, Kjaer SK, et al
    Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2015 Jul 7. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    April 2015
  71. MIZUNO M, Kajiyama H, Shibata K, Mizuno K, et al
    Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
    Br J Cancer. 2015;112:1376-83.
    PubMed     Text format     Abstract available


    March 2015
  72. MCPHAIL S, Johnson S, Greenberg D, Peake M, et al
    Stage at diagnosis and early mortality from cancer in England.
    Br J Cancer. 2015;112 Suppl 1:S108-15.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: